Navigation Links
CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007

Zurich, June 1, 2007-Cytos Biotechnology AG is delighted to inform you about the upcoming scientific presentations of its novel immunotherapeutic CYT003-QbG10 to treat allergic diseases. Recently, positive clinical results for CYT003-QbG10 were obtained and will be presented in different sessions at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI), taking place from June 9-13, 2007 in Göteborg, Sweden. The EAACI Congress has developed into one of the most important annual events in the field of Allergy in the world. For more information please visit ww.congrex.com/eaaci2007.

CYT003-QbG10 presentations at EAACI 2007: 1) Oral presentation of Abstract No. 146: Dust mite allergy - new treatment options. Dr. med. Thomas Kündig, Head of Research, Department of Dermatology, University Hospital Zurich, Switzerland will present the CYT003-QbG10 study findings relating to house dust mite allergy on Tuesday, June 12, 2007; Oral Abstract Session 26 - Novel developments in basic allergology; 3.30 - 5.00 pm (CET).

2) Poster presentation of Abstract No. 183: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy. Presentation is on Sunday, June 10, 2007; Poster Discussion Session 1 - Immunotherapy; 10.00 - 12.00 am (CET).

3) Poster presentation of Abstract No. 714: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel immunotherapy in patients suffering from house dust mite allergy. Presentation is on Sunday, June 10, 2007; Poster Session - Allergen SIT IV; 12.00 -1.30 pm (CET).

Background: CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the Immunodrug™ QbG10 which is comprised of the virus-like particle Qb f illed with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response in order to suppress an "allergic" Th2 type immune response. An earlier, open-label phase IIa study with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose showed excellent long-term efficacy in patients allergic to dust mites. Furthermore, two placebo-controlled phase IIa studies with CYT003-QbG10 delivered positive results in patients suffering from allergic rhinitis due to grass pollen allergy and house dust mite allergy. CYT003-QbG10 is currently being studied in clinical trials for the treatment of allergic rhinitis and atopic dermatitis.

Please feel free to contact us at the address below should you wish to receive further information, address questions, or arrange meetings with Cytos Biotechnology directly.

With best regards,

Claudine Blaser

For more information please contact:

Claudine Blaser, PhD Director Corporate Communications Cytos Biotechnology AG Wagistrasse 25, Postfach CH-8952 Schlieren (Zurich) Tel. +41 44 733 47 20 Fax. +41 44 733 47 18 e-mail: claudine.blaser@cytos.com www.cytos.com


'"/>




Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
5. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
6. Basilea Reports Positive Re-treatment Results from a Second Phase III Trial of Alitretinoin for Patients with Severe Chronic Hand Eczema
7. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
8. Data to be presented at AAN Meeting -Study results of drug candidate for MS
9. Data supporting three Antisoma programmes presented at AACR
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):